Hosted by Gynecologic Oncology · 🇺🇸 US · EN · 69 episodes
Established thought leaders with verified media credentials.
Stay informed with the latest research and emerging topics in gynecologic oncology through our monthly podcast series. Each episode features a dynamic conversation hosted by one of our Journal’s esteemed editors, who speaks with the authors of the Editor’s Choice article and the accompanying commentarial.
Gynecologic Oncology hosts Listen to Gynecologic Oncology, a science show with 69 episodes published.
Editor's Choice: Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding Editorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovatio
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review Moderator: Ursula A. Matulonis, MD; Dana-Farber
Editor's Choice: Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer Editorial: Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and p
Editor’s Choice: Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement Hosted by: Jose Alejandro Rauh-Hain, MD MPH Department of Gynecologic Oncology and Reproduct
Editor's Choice: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian
Editor’s Choice: Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment? Editorial: Towards personalizing PARP inhibitor maintenance therapy
Editor’s Choice: Reconsidering follow-up care in gynaecologic oncology: A scoping review exploring alternative approaches Editorial: Who is following up? Rethinking survivorship and surveillance Hosted by: Paola A Gehrig
Editor’s Choice: Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant Editorial: Does a diagnosis of breast cancer reduce ovarian cancer risk in BRCA1/2 carriers:Why is this a question? Ho
Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer Editor’s Choice: Safety and efficacy of mirvetuximab sora
Editor’s Choice: Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancer Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: Willia
Editor’s Choice: Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in
Editor’s Choice: Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology – A prospective randomized trial Editorial: Relax - It’s evidence-based: The role of hypnosis in managin
Editor’s Choice: TROP2 expression and therapeutic targeting in uterine carcinosarcoma Editorial: The search for new therapeutic options for uterine carcinosarcoma Hosted by: Amanda Nickles Fader, MD, Deputy Editor of Gyn
Editor’s Choice: STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective stoMAs Editorial: Diverting ileostomy: An ounce of prevention, but when? Hosted b
Editor’s choice: A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: A
Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consort
Editor’s Choice: Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrosp
Editor’s Choice: Clinical trial enrollment during first course of gynecologic cancer treatment and survival Editorial: Clinical trials are not the solution to inequities in cancer care Hosted by: Dr David Gaffney, MD, Ph
Editor’s Choice: Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma Editorial: Following the folate receptor: Expanding targeted treatment options in low
Editor’s Choice: The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study Editorial: Hormonal maintenance therapy f
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch Listen to Gynecologic Oncology, visit https://www.gynecologiconcology-online.net/multimedia/audio for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent science coverage.
Listen to Gynecologic Oncology is hosted by Gynecologic Oncology. The show is categorised under science (health) and has published 69 episodes.
Listen to Gynecologic Oncology has published 69 episodes.
Listen to Gynecologic Oncology regularly covers science, health, fitness. It sits in the science category, with a health focus.
Listen to Gynecologic Oncology is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Listen to Gynecologic Oncology hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Listen to Gynecologic Oncology average 24 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Listen to Gynecologic Oncology's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched today.
